0002001011-24-000078.txt : 20240826
0002001011-24-000078.hdr.sgml : 20240826
20240826201537
ACCESSION NUMBER: 0002001011-24-000078
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240822
FILED AS OF DATE: 20240826
DATE AS OF CHANGE: 20240826
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Korenberg Matthew E
CENTRAL INDEX KEY: 0001649903
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 241242936
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD
STREET 2: SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-08-22
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001649903
Korenberg Matthew E
555 HERITAGE DRIVE
SUITE 200
JUPITER
FL
33458
0
1
0
0
President & COO
0
Common Stock
2024-08-22
4
S
0
1157
105.54
D
67211
D
Common Stock
2024-08-23
4
S
0
2037
104.0945
D
65174
D
Common Stock
2024-08-23
4
S
0
4275
105.1319
D
60899
D
Common Stock
2024-08-26
4
S
0
6177
105.016
D
54722
D
Common Stock
2024-08-26
4
S
0
5212
106.3214
D
49510
D
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.2500 to $105.6500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.0000 to $105.4450. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.7200 to $105.6700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.8100 to $106.6900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
By: /s/ Andrew Reardon, Attorney-in-Fact For: Matthew E. Korenberg
2024-08-26